Joanna Mitri, MD
Internal Medicine · Boston, MANPI 1356582845
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,790 of the $51,783 with a category attached, or 82.6%. Novo Nordisk accounts for 85.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $29,052 and has fallen 99.8% since, to $50 in 2024. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $1362.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$44K
- Eli Lilly$5K
- Novo Nordisk AS$2K
- Orpyx Medical Technologies Inc.$500
- Insulet Corporation$155
- Johnson & Johnson$136
- plus $239 from 4 others
Across 37 payments — averaging $3454.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$128K
What the payments were for
- Consulting fees$42,79083%
- Speaking & faculty fees$5001%
- Travel & lodging$5,65311%
- Food & beverage$2,6845%
- Education$380%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $44,273 |
| Eli Lilly | 1 | $4,950 |
| Novo Nordisk AS | 1 | $1,530 |
| Orpyx Medical Technologies Inc. | 1 | $500 |
| Insulet Corporation | 3 | $155 |
| Johnson & Johnson | 1 | $136 |
| Mannkind Corporation | 2 | $119 |
| Sanofi | 1 | $50 |
| Boehringer Ingelheim | 2 | $38 |
| Abbott | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,783 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 94 | $103,197 |
| JardianceEmpagliflozin | 102 | $87,911 |
| OzempicSemaglutide | 38 | $53,304 |
| MounjaroTirzepatide | 18 | $31,475 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $27,643 |
| JanuviaSitagliptin Phosphate | 18 | $23,751 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $4,862 |
| HumalogInsulin Lispro | 15 | $3,689 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 26 | $2,811 |
| LantusInsulin Glargine,hum.Rec.Anlog | 14 | $2,643 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,584 |
| Novolog FlexpenInsulin Aspart | 13 | $1,766 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 16 | $1,571 |
| Ezetimibe | 24 | $990 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 16 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $38 | $87,911102 claims |
| Novo NordiskOzempic | $44,273 | $53,30438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Boston
- David SchenkeinBoston$5M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
- Nancy GaglianoBoston$358K
- Fatima StanfordBoston$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.